The European Medicines Agency recorded 22,496 individual case safety reports for human papillomavirus vaccines types 6, 11, 16 and 18. 17,490 were classified as serious. The EMA maintains that Gardasil 9 is safe and effective, with ONLY 15,000 reports to pharmaco-vigilance and 23,000 for the previous product.
Published on 4 February 2026 by pgibertie
On adrreports.eu, HPV vaccines are listed separately:
- Gardasil / Silgard (quadrivalent: types 6, 11, 16, 18).
- Gardasil 9 (nonavalent).
- Cervarix (bivalent: 16, 18).
*The dominance of nervous (headaches, dizziness, paresthesias, syncope, etc.), musculoskeletal (joint/muscular pain) and psychiatric (anxiety, chronic fatigue-like) disorders in 12-17 year-olds is a known historical pattern for HPV vaccines, especially Gardasil quadrivalent. The EMA has investigated these signals in depth (2015 review on POTS/CRPS/CFS).
Cumulative totals since 2006-2007 are much higher than 22,496 (tens to hundreds of thousands of reports in total for all HPV vaccines combined, according to historical EMA reviews).
Most frequent System Organ Class (SOC) reactionsClassified by decreasing total (MedDRA):
- Nervous system disorders: 11,987 cases (~53% of the total) – Highly prevalent in 12-17 year olds (6,474) and 18-64 year olds (2,430). Includes headaches, dizziness, etc., often benign.
- General disorders and administration site conditions: Not explicitly listed in your extract, but often high in these reports.
- Gastrointestinal disorders: 4,689
- Skin and subcutaneous tissue disorders: 3,561
- Injuries, poisoning and procedural complications: 3,505
- Musculoskeletal and connective tissue disorders: 1,034 (or ~1,030 depending on display)
- Eye disorders: 2,003
- Additional examinations: €2,295
- Psychiatric disorders: ~2,607 (if included in “Psychiatric issues” or similar)
- Others of note: cardiac (1,423), immune (1,231), respiratory (1,712), etc.
Adolescents (aged 12-17) dominate many groups (nervous, gastrointestinal, musculoskeletal, etc.), which corresponds to the patterns observed historically for mRNA vaccines in young people (e.g. rare myo-pericarditis reported and monitored).
A 14-year-old boy dies after receiving the human papillomavirus (HPV) vaccine ” A previously healthy 14-year-old boy developed headaches, fatigue, localised weakness and confusion 3 weeks after receiving the HPV vaccine and died of a brain hernia.
